EANM guideline for the preparation of an Investigational Medicinal Product Dossier (IMPD)
- 1k Downloads
The preparation of an Investigational Medicinal Product Dossier (IMPD) for a radiopharmaceutical to be used in a clinical trial is a challenging proposition for radiopharmaceutical scientists working in small-scale radiopharmacies. In addition to the vast quantity of information to be assembled, the structure of a standard IMPD is not well suited to the special characteristics of radiopharmaceuticals. This guideline aims to take radiopharmaceutical scientists through the practicalities of preparing an IMPD, in particular giving advice where the standard format is not suitable. Examples of generic IMPDs for three classes of radiopharmaceuticals are given: a small molecule, a kit-based diagnostic test and a therapeutic radiopharmaceutical.
KeywordsRadiopharmaceutical Clinical trial Investigational medicinal product Guideline
- 1.European Association of Nuclear Medicine Radiopharmacy Committee. Guidelines on current good radiopharmacy practice (cGRPP) in the preparation of radiopharmaceuticals, version 2, 2007. http://www.eanm.org/publications/guidelines/gl_radioph_cgrpp.pdf. Accessed 11 July 2014.
- 3.European Parliament and the Council of the European Union. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Off J Eur Union 2001;L(121):34–44.Google Scholar
- 4.European Parliament and Council of the European Union. Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. Off J Eur Union 2014;L(158):1–76.Google Scholar
- 5.European Medicines Agency Committee for Medicinal Products for Human Use. Guideline on the requirements for quality documentation concerning investigational medicinal products in clinical trials. 2012. EMA/CHMP/BWP/534898/2008.Google Scholar
- 6.European Union Enterprise Directorate-General. Detailed guidance for the request for authorisation of a clinical trial on a medicinal product for human use to the competent authorities, notification of substantial amendments and declaration of the end of the trial. Revision 2. 2005. ENTR/F2/BL D(2003).Google Scholar
- 7.International Conference on Harmonisation. Guideline for good clinical practice. E6(R1). 1996. www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html. Accessed 11 July 2014.
- 8.European Parliament and the Council of the European Union. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the community code relating to medicinal products for human use. Off J Eur Union 2004;L(311):67–128.Google Scholar
- 9.EANM Radiopharmacy Committee. Specialisation in radiopharmacy. http://www.eanm.org/committees/radiopharmacy/specialisation.php?navId=234). Accessed 11 July 2014.
- 10.European Medicines Agency Committee for Medicinal Products for Human Use. Guideline on radiopharmaceuticals. 2008. EMEA/CHMP/QWP/306970/2007.Google Scholar
- 11.Fernelius WC, Coyle TD, Powell WH. Nomenclature of inorganic chemistry. 12. Isotopically modified compounds. Pure Appl Chem 1979;51:1981–94.Google Scholar
- 12.European Directorate for the Quality of Medicines and Healthcare. Radiopharmaceutical preparations. European Pharmacopoeia, 8th edition, 2013. Strasbourg: Council of Europe.Google Scholar
- 13.European Medicines Agency. ICH Q2(R1): Note for guidance on validation of analytical procedures: text and methodology. 1995. CPMP/ICH/381/95.Google Scholar
- 14.European Medicines Agency. ICH Q3B(R2): Note for guidance on impurities in new drug products. 2006. CPMP/ICH/2738/99.Google Scholar
- 15.European Medicines Agency. ICH Q3A(R2): Note for guidance on impurities testing: impurities in new drug substances. 2006. CPMP/ICH/2737/99.Google Scholar